Protein kinase inhibitors: emerging pharmacophores 1997 - 2000

Bibliography

• TRAXLER P: Tyrosine kinase inhibitors in cancer treatment (Part II). Exp. Opin. Ther. Patents (1998) 8(12):1599–1625.
   Web of Science ®Google Scholar
• ••A very complete review of the kinase inhibitor literature,focusing on cancer. Part I (Exp. Opin. Ther. Patents (1997) 7(6):571–588) should also be considered to provide a historical perspective.
   Google Scholar
• BRIDGES A: Current progress towards the develop- ment of tyrosine kinase inhibitors as anticancer agents. Emerging Drugs (1998) 3:279–292.
   Google Scholar
• ••Updates on important preclinical kinase inhibitors, as wellas agents undergoing human clinical trials, in a tabular format.
   Google Scholar
• MYERS MR, HE W, HULME C: Inhibitors of tyrosine kinase involved in inflammation and autoimmune disease. Curr. Pharm. Design (1997) 3(5):473–502.
   Google Scholar
• ••An important review of kinase inhibitor pharmacophoresbefore 1997.
   Google Scholar
• GARCIA-ECHEVERRIA C, TRAXLER P: ATP site-directed competitive and irreversible inhibitors of protein kinases. Med. Res. Rev. (2000) 20(1):28–57.
   PubMedGoogle Scholar
• TRAXLER P, FURET P: Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. (1999) 82 (2-3):195–206.
   PubMed Web of Science ®Google Scholar
• ADAMS JL, LEE D: Recent progress towards the identifi-cation of selective inhibitors of serine/threonine protein kinases. Curr. Opin. Drug Discov. Dev. (1999) 2(2):96–109.
   PubMed Web of Science ®Google Scholar
• MCMAHON G, SUN L, LIANG C, TANG C: Protein kinaseinhibitors: structural determinants for target specificity. Curr. Opin. Drug Discov. Dev. (1998) 1 (2):131–146.
   PubMedGoogle Scholar
• BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Exp. Opin. Ther. Patents (2000) 10(0:25–37.
   Web of Science ®Google Scholar
• •Provides an overview of the pyridyl-imidazole (SB- 19203580) p38 inhibitor class.
   Google Scholar
• LE COUTRE P, MOLOGNI L, CLERIS L et al: In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. (1999) 91(2):163–168.
   PubMedGoogle Scholar
• ZIMMERMANN J, BUCHDUNGER E, METT H, MEYER T, LYDON NB, TRAXLER P: Ph enylamin opyrimidin e (PAP) -derivatives: anew class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. (1996) 6(10:1221–1226.
   Google Scholar
• BILDER G, WENTZ T, LEADLEY R et al: Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation (1999) 99:3292–3299.
   Google Scholar
• DOLLE RE, DUNN JA, BOBKO M et al.: 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular 13-type platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. (1994) 37(17):2627–2629.
   PubMedGoogle Scholar
• HANKE JH, GARDNER JP, DOW RL et al: Discovery of a novel, potent and src family-selective tyrosine kinase inhibitor. j Biol. Chem. (1996) 271 (2):695–701.
   PubMed Web of Science ®Google Scholar
• MISSBACH M, ALTMANN E, WIDLER L et al: Substituted 5,7-diphenylpyrrolo [2,3d]pyrimidines: potent inhibi-tors of the tyrosine kinase c-src. Bioorg. Med. Chem. Lett. (2000) 10:945–949.
   PubMedGoogle Scholar
• BRIDGES AJ, ZHOU H, CODY DR et al.: Tyrosine kinase inhibitors. 8 An unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxy quinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. (1996) 39:267–276.
   Google Scholar
• KUBO K, SHIMIZU T, OHYAMA S et al.: A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation. Bioorg. Med. Chem. Lett. (1997) 7(23):2935–2940.
   Google Scholar
• WISSNER A, BERGER DM, BOSCHELLI DH et al.: 4 -Anilin o-6,7 -dialkoxyquin oline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilimo-6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. (2000) 43:3244–3256.
   PubMed Web of Science ®Google Scholar
• ••Discovery of the 3-cyanoquinoline kinase inhibitor classthrough rational design.
   Google Scholar
• YE F, BOSCHELLI DH, WANG D et al: Inhibition of src kinase activity by a series of 4-anilino-3-cyanoquinolines. Book of Abstracts, 22011 ACS National Meeting. Washington, USA (2000) MEDI–52.
   Google Scholar
• FONG TAT, SHAWYER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1 /KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMedGoogle Scholar
• •In vitro and in vivo profile of SU5416.
   Google Scholar
• SUN L, TRAN N, TANG F et al.: Synthesis and biologicalevaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med. Chem. (1998) 41:2588–2603.
   PubMed Web of Science ®Google Scholar
• SUN L, TRAN N, LIANG C et al.: Identification of substi-tuted 3[(4,5,6,7-tetrahydro-1H-indo1-2-y1)methyl ene]-1,3-dihydroindo1-2-ones as growth factor receptor inhibitors for VEGF- R2 (flk- 1 /KDR), FGF- R1 and PDGF- RI3 tyrosine kinases. J. Med. Chem. (2000) 43:2655–2663.
   PubMed Web of Science ®Google Scholar
• RICE AG: 3-Substituted indolin-2-ones are potent andselective inhibitors of cyclin-dependent kinases and exhibit effects on cell cycle and tumor growth. Proceed-ings of the 91st Meeting of the American Association for Cancer Research. San Francisco, USA (2000) Abstract 1592.
   Google Scholar
• VEAL JM, BRAMSON N, DICKERSON S et al.: Identificationof inhibitors of cyclin-dependent kinases. Book of Abstracts, 218th ACS National Meeting. New Orleans, USA (1999) MEDI–314.
   Google Scholar
• DAVIS ST, BRAMSON N, DICKERSON S et al.: Novel cyclindependent kinase inhibitors prevent chemotherapy-induced alopecia. Proceedings of the 91st Meeting of the American Association for Cancer Research. San Francisco, USA (2000):Abstract 200.
   Google Scholar
• MOHAMMADI M, MCMAHON G, SUN L et al.: Structures ofthe tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (1997) 276:955–960.
   PubMed Web of Science ®Google Scholar
• LACKEY K, CORY M, DAVIS R et al.: The discovery ofpotent c-raf1 kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 1 0 (3):223–226.
   Google Scholar
• CHENG S, COMER DD, FREIRE-MONAR J et al.:Onxindolidene derivatives as p38 MAP kinase inhibi-tors. Book of Abstracts, 219th ACS National Meeting San Francisco, USA (2000) MEDI–282.
   Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK et al: 5U6668 is apotent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. (200) 60(15):4152–4160.
   Google Scholar
• •An overview of the pharmacological profile of 5U6668.
   Google Scholar
• SUN L, TRAN N, HANG C et al.: Design, synthesis andevaluations of substituted 3-[(3-or4-carboxy-ethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J. Med. Chem. (1999) 42:5120–5130.
   PubMed Web of Science ®Google Scholar
• REDMAN A, JOHNSON JS, DALLY R et al.: P38 kinaseinhibitors for the treatment of arthritis and osteopo-rosis: thienyl, furyl and pyrrolyl ureas. Bioorg. Med. Chem. Lett. (2001) 11(1):9–12.
   PubMedGoogle Scholar
• DUMAS J, SIBLEY R, RIEDL B et al.: Discovery of a newclass of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10 (18):2047–2050.
   PubMedGoogle Scholar
• DUMAS J, HATOUM-MOKDAD H, SIBLEY R et al.: 1-Phenyl-5-pyrazoly1 ureas: potent and selective p38 kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10 (18):2051–2054.•[31] and [32] are the first publications focusing on urea-based kinase inhibitors.
   Google Scholar
• RANGES GE, BHARGAVA A, BORTOLON E et al.: Pharma-cological characterization of p38 kinase inhibitors from the urea class. Book of Abstracts, 220hACS National Meeting Washington, USA (2000) MEDI–149.
   Google Scholar
• LOWINGER TB, RIEDL B, WOOD J et al.: Discovery of anew class of potent raf kinase inhibitors: structure activity relationships. Book of Abstracts, 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Amsterdam, Netherlands (2000) Abstract 335.
   Google Scholar
• TECLE H, BARRETT S, BRIDGES A et al.: Potent and selective MEK inhibitors: synthesis and SAR of 2-(4-iodo-phenylamino)benzoic acids and hydrox-amic acid derivatives thereof. Proceedings of the 90th Meeting of the American Association for Cancer Research. Philadelphia, USA (1999) Abstract 806.
   Google Scholar
• ••Novel, non-ATP-competitive inhibitors of MEK.
   Google Scholar
• BARRETT SD, BRIDGES AJ, LEOPOLD WR et al.:N-alkoxy-2-(4-iodo-phenylamino)-benzamides: 0-alkyl benhydroxamate esters as a novel class of potent MEK inhibitors. Book of Abstracts, 218th ACS National Meeting New Orleans, USA (1999) MEDI–203.
   Google Scholar
• SEBOLT-LEOPOLD JS, DUDLEY DT, HERRERA R et al.:Blockade of the MAP kinase pathway suppresses growth of colon tumors in viva Nature Med. (1999) 5 (7):810–816.
   Google Scholar
• BOLD G, ALTMANN KH, FREI J et al.: New anilin op h th a-lazines as potent and orally well absorbed inhibitors of the VEGFreceptor tyrosine kinases useful as antago-nists of tumor-driven angiogenesis. J. Med. Chem. (2000) 43:2310–2323.
   PubMed Web of Science ®Google Scholar
• ••First published examples of phthalazine-based kinaseinhibitors.
   Google Scholar
• WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administra-tion. Cancer Res. (2000) 60 (8) 2178–2189.
   PubMed Web of Science ®Google Scholar
• •Orally-active KDR inhibitor PTK787.
   Google Scholar
• HIGLEY CA, YUE EW, BENFIELD PA et al.: Alkyl-substituted indenopyrazoles as inhibitors of cyclin-dependent kinases. Book of Abstracts, 219th ACS National Meeting. San Francisco, USA (2000) MEDI–39.
   Google Scholar
• GRAY NS, WODICKA L, THUNNISSEN AMWH et al.: Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science (1998) 281:533–538.
   PubMed Web of Science ®Google Scholar
• KUNICK C: Fused azepinones with antitumor activity. Curr. Pharm. Design (1999) 5:181–194.
   PubMedGoogle Scholar
• •Overview of the azepinone class, including the paullones and earlier structural subtypes.
   Google Scholar
• ZAHAREVITZ DW, GUSSIO R, LEOST M et al.: Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. (1999) 59:2566–2569.
   PubMed Web of Science ®Google Scholar
• GUSSIO R, ZAHAREVITZ DW, MCGRATH CF et al.: Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase AntiCancer Drug Design (2000) 15:53–66.
   Google Scholar
• SCHULTZ C, LINK A, LEOST M et al.: Paullon es, a series ofcyclin-dependent kinase inhibitors: synthesis, evalua-tion of CDK1 /cyclin B inhibition and in vitro antitumor activity. J Med. Chem. (1999) 42:2909–2919.
   PubMed Web of Science ®Google Scholar
• KUNICK C, SCHULTZ C, LEMCKE T et al: 2-Substitutedpaullones: CDK1/cyclin B -inhibiting property and in vitro antiproliferative activity. Bioorg. Med. Chem. Lett. (2000) 10:567–569.
   PubMed Web of Science ®Google Scholar
• MISRA RN, RAWLINS DB, BATORSKI R et al.:5-Acylpyrazolo[3,4-b]pyrimidines: potent inhibitors of cyclin-dependent kinases. Proceedings of the 91st Meeting of the American Association for Cancer Research. San Francisco, USA (2000) Abstract 3002.
   Google Scholar
• UEHATA M, ISHIZAKI T, SATOH H et al: Calcium sensiti-zation of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (1997) 389(30)990–994.
   Google Scholar
• SAHAI E, ISHIZAKI T, NARUMIYA S, TREISMAN R:Transformation mediated by RhoA requires activity of ROCK kinases. Curr. Biol. (1999) 9:136–145.
   PubMedGoogle Scholar
• ISHIZAKI T, UEHATA M, TAMECHIKA I et al: Pharma-cological properties of Y-27632, a specific inhibitor of Rho-associated kin ases. Mol. Pharmacol. (2000) 57 (5):976–983.
   PubMed Web of Science ®Google Scholar
• ITOH K, YOSHIOKA K, AKEDO H, UEHATA M, ISHIZAKIT, NARUMIYA S: An essential part for Rho-associated linase in the transcellular invasion of tumor cells. Nature Med. (1999) 5(2):221–225.
   PubMedGoogle Scholar
• SAWADA N, ITOH H, UEYAMA K et al.: Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation (2000) 101 (17):2030–2033.
   PubMedGoogle Scholar
• KIM SH: Structure-based inhibitor design for CDK2, a cell cycle controlling protein kinase. Pure Appl. Chem. (1998) 70(3):555–565.
   Google Scholar
• ••Provides useful x-ray crystallography data of various inhibi-tors bound to cdk2.
   Google Scholar
• LAWRIE AM, NOBLE MEM, TUNNAH P, BROWN NR, JOHNSON LN, ENDICOTT JA: Protein kinase inhibition by Staurosporine revealed in details of the molecular interaction with cdk2. Nat. Struct. Biol. (1997) 4:796–801.
   PubMedGoogle Scholar
• HANKS SK, HUNTER T: The eucaryotic protein kinasesup erfamily: kinase (catalytic) domain structure and classification. FASEB (1995) 9:576–596.
   PubMed Web of Science ®Google Scholar
• SAUSVILLE EA: Protein kinase antagonists: interimchallenges and issues. AntiCancer Drug Design (2000) 15:1–3.
   PubMedGoogle Scholar
• FRYE SV: Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem. Biol. (1999) 6(1):R3–R7.
   Google Scholar
• CODY WL, LIN Z, PANEK R, ROSE DW, RUBIN JR: Progress in the development of inhibitors of SH2 domains. Curr. Pharm. Des. (2000) 6(0:59–98.
   PubMedGoogle Scholar
• •Comprehensive overview of recent developments in this area.
   Google Scholar